Tina Rydén-Bergsten
A pharmacist by training, I have spent three decades in industry and over 15 years at AstraZeneca focusing on improving the lives of people with cardiovascular, renal and metabolic (CVRM) diseases.
At AstraZeneca I have had the chance to work across the full spectrum of drug development, helping me hone both my clinical and commercial acumen. Roles have included Product Lead in Early and Late-stage CVRM drug development, Global Commercial Director and Pricing and Market Access Director. I have supported drug approvals, investment decisions, IPOs, clinical deals and health authority negotiations.
I thrive on developing high-performing teams with entrepreneurial and innovative mindsets. Together, we have made significant scientific breakthroughs, including pioneering the development of antisense oligonucleotide and beta-cell imaging for regenerative therapies in diabetes. With the growing burden of cardiovascular, metabolic and renal diseases around the world, I am proud to lead projects teams with a focus on finding novel targets to stop progression of these devastating diseases.
Working with both clinical and commercial colleagues, I thrive on developing high-performing teams with entrepreneurial and innovative mindsets.
CURRENT ROLE
2011 - 2021
2008 – 2010
2007-2008
Featured publications
Veeva ID: Z4-60858
Date if preparation: February 2024